Delisheng, a Chinese medicinal compound, exerts anti-proliferative and pro-apoptotic effects on HepG2 cells through extrinsic and intrinsic pathways

Molecular Biology Reports

Volumn 37, Issue 7, 2010, Pages 3407-3412

  Lu, Chuang Xin ^a   Nan, Ke Jun ^a   Nie, Yan Li ^a   Hai, Ya Nan ^a   Jiao, Min ^a  

^a XI'AN JIAOTONG UNIVERSITY   (China)

Author keywords

Apoptosis; Bcl 2; Caspase; Delisheng; DR5; HepG2

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; DEATH RECEPTOR; DELISHENG; FLUORESCEIN ISOTHIOCYANATE; LIPOCORTIN 5; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL ASSAY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL STRAIN HEPG2; CELL VIABILITY; CHINESE MEDICINE; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG EFFECT; DRUG MECHANISM; ENZYME INDUCTION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; LIVER CELL CARCINOMA; PROTEIN MODIFICATION; SIGNAL TRANSDUCTION; UPREGULATION;

ANNEXIN A5; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BLOTTING, WESTERN; CASPASES; CELL CYCLE; CELL PROLIFERATION; CELL SURVIVAL; DRUG SCREENING ASSAYS, ANTITUMOR; DRUGS, CHINESE HERBAL; FLOW CYTOMETRY; FLUORESCEIN-5-ISOTHIOCYANATE; HEP G2 CELLS; HUMANS; PROPIDIUM; RECEPTORS, DEATH DOMAIN; SIGNAL TRANSDUCTION;

EID: 77956951234     PISSN: 03014851     EISSN: 15734978     Source Type: Journal    
DOI: 10.1007/s11033-009-9930-7     Document Type: Article

References (38)

1. K Okuda 2000 Hepatocellular carcinoma J Hepatol 32 225 237 1:STN:280:DC%2BD3c7ptFWmsw%3D%3D 10.1016/S0168-8278(00)80428-6 10728807
2. P Rougier E Mitry JC Barbare J Taieb 2007 Hepatocellular carcinoma (HCC): an update Semin Oncol 34 S12 S20 1:CAS:528:DC%2BD2sXmtV2ku7c%3D 10.1053/j.seminoncol.2007.01.007 17449346 (Pubitemid 46590363)
3. JM Llovet A Burroughs J Bruix 2003 Hepatocellular carcinoma Lancet 362 1907 1917 10.1016/S0140-6736(03)14964-1 14667750 (Pubitemid 37518510)
4. JM Llovet J Fuster J Bruix 2004 The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma Liver Transplant 10 S115 S120 10.1002/lt.20034
5. C Rui-Chuan S Jin-Hua O Gao-Liang C Ke-Xia L Jin-Quan X Xiao-Guang 2002 Induction of differentiation in human hepatocarcinoma cells by isoverbascoside Planta Med 68 370 372 10.1055/s-2002-26759 11988868 (Pubitemid 34494055)
6. T Efferth M Davey A Olbrich G Rucker E Gebhart R Davey 2002 Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug resistant human CCRF-CEM leukemia cells Blood Cells Mol Dis 28 160 168 10.1006/bcmd.2002.0492 12064912 (Pubitemid 34743750)
7. M Mabed L El-Helw S Shamaa 2004 Phase II study of viscum fraxini-2 in patients with advanced hepatocellular carcinoma Br J Cancer 90 65 69 1:CAS:528:DC%2BD2cXhtFKnsg%3D%3D 10.1038/sj.bjc.6601463 14710208 (Pubitemid 38174940)
8. M Jang L Cai GO Udeani, et al. 1997 Cancer chemopreventive activity of resveratrol, a natural product derived from grapes Science 275 218 220 1:CAS:528:DyaK2sXks1Sjtw%3D%3D 10.1126/science.275.5297.218 8985016
9. JT Cheng 2000 Drug therapy in Chinese traditional medicine J Clin Pharmacol 40 445 450 1:STN:280:DC%2BD3c3ms1Gmug%3D%3D 10.1177/00912700022009198 10806595
10. Y Kamano A Kotake H Hashima, et al. 1998 Structure-cytotoxic activity relationship for the toad poison bufadienolides Bioorg Med Chem 6 1103 1115 1:CAS:528:DyaK1cXlsVansLY%3D 10.1016/S0968-0896(98)00067-4 9730247 (Pubitemid 28464541)
11. DY Lee M Yasuda T Yammoto, et al. 1997 Bufalin inhibits endothelial cell proliferation and angiogenesis in vitro Life Sci 60 127 134 1:CAS:528: DyaK28XnsFSgsLg%3D 10.1016/S0024-3205(96)00602-9 9000118 (Pubitemid 27022720)
12. JY Yeh WJ Huang SF Kan, et al. 2003 Effects of bufalin and cinobufagin on the proliferation of androgen dependent and independent prostate cancer cells Prostate 54 112 124 1:CAS:528:DC%2BD3sXhtlShtL4%3D 10.1002/pros.10172 12497584 (Pubitemid 36120327)
13. Ke-Qi Han G Huang W Gu Y-H Su X-Q Huang C-Q Ling 2007 Anti-tumour activities and apoptosis-regulated mechanisms of bufalin on the orthotopic transplantation tumour model of human hepatocellular carcinoma in nude mice World J Gastroenterol 13 3374 3379 1:CAS:528:DC%2BD2sXovFWmtLg%3D 17659679
14. Z Shu-wu Z Shi-yi S Ji-chun Q Xiao-wei 2009 Primary research on Chinese medicine treatment of androgen-independent prostate cancer Chin J Integr Med 15 168 169 10.1007/s11655-009-0168-y
15. P Li D Nijhawan I Budihardjo SM Srinivasula M Ahmad ES Alnemri X Wang 1997 Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade Cell 91 479 489 1:CAS:528: DyaK2sXnsFGls70%3D 10.1016/S0092-8674(00)80434-1 9390557
16. S Nagata 1997 Apoptosis by death factor Cell 88 355 365 1:CAS:528:DyaK2sXhtFahtbg%3D 10.1016/S0092-8674(00)81874-7 9039262 (Pubitemid 27131377)
17. S Luna-More B Weil D Bautista E Garrido P Florez C Martinez 2004 Bcl-2 protein in normal, hyperplastic and neoplastic breast tissues. A metabolite of the putative stem-cell subpopulation of the mammary gland Histol Histopathol 19 457 463 1:CAS:528:DC%2BD2cXjsVGntrY%3D 15024706
18. M van Gurp N Festjens G van Loo X Saelens P Vandenabeele 2003 Mitochondrial intermembrane proteins in cell death Biochem Biophys Res Commun 304 487 497 10.1016/S0006-291X(03)00621-1 12729583 (Pubitemid 36506521)
19. S Cory JM Adams 2002 The Bcl2 family: regulators of the cellular life-or-death switch Nat Rev Cancer 2 647 656 1:CAS:528:DC%2BD38Xmslamsrw%3D 10.1038/nrc883 12209154 (Pubitemid 37328916)
20. MH Lam Q Liu SJ Elledge JM Rosen 2004 Chk1 is haploinsufficient for multiple functions critical to tumor suppression Cancer Cell 6 45 59 1:CAS:528:DC%2BD2cXmtlKnt7g%3D 10.1016/j.ccr.2004.06.015 15261141 (Pubitemid 38903161)
21. J Henry-Mowatt C Dive JC Martinou D James 2004 Role of mitochondrial membrane permeabilization in apoptosis and cancer Oncogene 23 2850 2860 1:CAS:528:DC%2BD2cXivFKmsb4%3D 10.1038/sj.onc.1207534 15077148 (Pubitemid 38638847)
22. ZN Oltvai CL Milliman SJ Korsmeyer 1993 Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death Cell 74 609 619 1:CAS:528:DyaK3sXms1eqtbs%3D 10.1016/0092-8674(93)90509-O 8358790 (Pubitemid 23259742)
23. G Del Poeta A Venditti MI Del Principe, et al. 2003 Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML) Blood 101 2125 2131 10.1182/blood-2002-06-1714 12424199 (Pubitemid 36302046)
24. PJ Dlugosz LP Billen MG Annis, et al. 2006 Bcl-2 changes conformation to inhibit Bax oligomer izat ion EMBO J 25 2287 2296 1:CAS:528:DC%2BD28XltlGlurk%3D 10.1038/sj.emboj.7601126 16642033 (Pubitemid 44012212)
25. Y Sedletska MJ Giraud-Panis JM Malinge 2005 Cisplatin is a DNA damaging antitumour compound triggering multifactorial biochemical responses in cancer cells: importance of apoptotic pathways Curr Med Chem Anticancer Agents 5 251 265 1:CAS:528:DC%2BD2MXktlSmsrw%3D 10.2174/1568011053765967 15992353 (Pubitemid 40655276)
26. A Ryningen E Ersvaer AM Oyan, et al. 2006 Stress-induced in vitro apoptosis of native human acute myelogenous leukemia (AML) cells shows a wide variation between patients and is associated with low BCL-2:Bax ratio and low levels of heat shock protein 70 and 90 Leuk Res 30 1531 1540 1:CAS:528:DC%2BD28XhtFWitLbI 10.1016/j.leukres.2006.02.014 16600371 (Pubitemid 44573475)
27. SJ Riedl Y Shi 2004 Molecular mechanisms of caspase regulation during apoptosis Nat Rev Mol Cell Biol 5 897 907 1:CAS:528:DC%2BD2cXptFemsL0%3D 10.1038/nrm1496 15520809 (Pubitemid 39486541)
28. G Nuneza MA Benedict Y Hu N Inohara 1998 Caspases: the proteases of the apoptotic pathway Oncogene 17 3237 3245 10.1038/sj.onc.1202581
29. T Fan L Han R Cong J Liang 2005 Caspase family proteases and apoptosis Acta Biochim Biophys Sin 37 719 727 1:CAS:528:DC%2BD2MXhtlWnsbbO 10.1111/j.1745-7270.2005.00108.x 16270150 (Pubitemid 44890981)
30. XD Zhang T Nguyen WD Thomas JE Sanders P Hersey 2000 Mechanisms of resistance of normal cells to TRAIL induced apoptosis vary between different cell types FEBS Lett 482 193 199 1:CAS:528:DC%2BD3cXntF2qtrY%3D 10.1016/S0014-5793(00)02042-1 11024459
31. M Dejosez U Ramp C Mahotka, et al. 2000 Sensitivity to TRAIL/APO-2L-mediated apoptosis in human renal cell carcinomas and its enhancement by topotecan Cell Death Differ 7 1127 1136 1:CAS:528: DC%2BD3cXovFWgsb0%3D 10.1038/sj.cdd.4400746 11139287
32. RK Srivastava 2001 TRAIL/Apo-2L: mechanisms and clinical applications in cancer Neoplasia 3 535 546 1:CAS:528:DC%2BD38XksFKjtQ%3D%3D 10.1038/sj.neo. 7900203 11774036 (Pubitemid 33151020)
33. G Pan K O'Rourke AM Chinnaiyan, et al. 1997 The receptor for the cytotoxic ligand TRAIL Science 276 111 113 1:CAS:528:DyaK2sXitl2jsL4%3D 10.1126/science.276.5309.111 9082980 (Pubitemid 27161256)
34. G Pan J Ni YF Wei G Yu R Gentz VM Dixit 1997 An antagonist decoy receptor and a death domain-containing receptor for TRAIL Science 277 815 818 1:CAS:528:DyaK2sXlt1eksro%3D 10.1126/science.277.5327.815 9242610 (Pubitemid 27366732)
35. A Ashkenazi VM Dixit 1999 Apoptosis control by death and decoy receptors Curr Opin Cell Biol 11 255 260 1:CAS:528:DyaK1MXisFWlsbk%3D 10.1016/S0955- 0674(99)80034-9 10209153 (Pubitemid 29164042)
36. I Lavrik A Golks PH Krammer 2005 Death receptor signaling J Cell Sci 118 265 267 1:CAS:528:DC%2BD2MXhslymtbg%3D 10.1242/jcs.01610 15654015 (Pubitemid 40277339)
37. H Wajant 2003 Death receptors Essays Biochem 39 53 71 1:CAS:528:DC%2BD2cXivFCiu7o%3D 14585074
38. C Brenner G Kroemer 2000 Apoptosis: mitochondria-the death signal integrators Science 289 1150 1151 1:CAS:528:DC%2BD3cXmt1Wjurg%3D 10.1126/science.289.5482.1150 10970229 (Pubitemid 30650720)